期刊
IMMUNOBIOLOGY
卷 223, 期 1, 页码 125-134出版社
ELSEVIER GMBH, URBAN & FISCHER VERLAG
DOI: 10.1016/j.imbio.2017.10.002
关键词
Adjuvant; B cell; C3d; C4BP; Complement receptor
类别
资金
- Chinese Scholarship for excellence/DFHS
- Wellcome Trust [WT068541]
- BBSRC [BB/N022165/1]
- Northern Counties Kidney Research Fund
- Newcastle Joint health care charities
- Biotechnology and Biological Sciences Research Council [BB/N022165/1] Funding Source: researchfish
- Medical Research Council [MC_PC_15030] Funding Source: researchfish
- BBSRC [BB/N022165/1] Funding Source: UKRI
- MRC [MC_PC_15030] Funding Source: UKRI
The use of C3d, the final degradation product of complement protein C3, as a natural adjuvant has been widely examined since the initial documentation of its immunogenicity-enhancing properties as a consequence of binding to complement receptor 2. Subsequently it was demonstrated that these effects are most evident when oligomeric, rather than when monomeric forms of C3d, are linked to various test protein antigens. In this study, we examined the feasibility of enhancing the adjuvant properties of human C3d further by utilizing C4b-binding protein (C4BP) to provide an oligomeric arrayed scaffold fused to the model antigen, tetanus toxin C fragment (TTCF). High molecular weight, C3d-containing oligomeric vaccines were successfully expressed, purified from mammalian cells and used to immunize groups of mice. Surprisingly, anti-TTCF antibody responses measured in these mice were poor. Subsequently we established by in vitro and in vivo analysis that, in the presence of mouse C3, human C3d does not interact with either mouse or even human complement receptor 2. These data confirm the requirement to develop murine versions of C3d based adjuvant compounds to test in mice or that mice would need to be developed that express both human C3 and human CR2 to allow the testing of human C3d based adjuvants in mouse in any capacity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据